AQST
Aquestive Therapeutics, Inc.
AQST's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over AQST overall, supported by lower modeled downside and stronger fundamentals.
AQST Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AQST's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AQST PE Valuation
AQST has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AQST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AQST's revenue to grow and its profitability to improve, with its earnings holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over AQST on the outlook, with more favorable earnings expectations.
AQST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.64 | +$0.06 |
| Q2 2026 | -$0.65 | +$0.04 |
| Q1 2026 | -$0.61 | -$0.03 |
| Q4 2025 | -$0.78 | -$0.27 |
| Q3 2025 | -$0.70 | -$0.26 |
| Q2 2025 | -$0.69 | -$0.35 |
| Q1 2025 | -$0.58 | -$0.17 |
| Q4 2024 | -$0.51 | -$0.38 |
AQST is still losing money, but far less than before: $0.64 per share over the past year, against $2.63 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AQST on earnings quality, reporting a profit while its opponent remains loss making.
AQST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.6M | -41% |
| Q2 2026 | $13.8M | +38% |
| Q1 2026 | $14.4M | +66% |
| Q4 2025 | $13M | +9.7% |
| Q3 2025 | $12.8M | -5.4% |
| Q2 2025 | $10M | -50% |
| Q1 2025 | $8.7M | -28% |
| Q4 2024 | $11.9M | -10% |
AQST's revenue is growing: $8M last quarter, down 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -191% | -102 points |
| Q2 2026 | -60% | +54 points |
| Q1 2026 | -29% | +193 points |
| Q4 2025 | -222% | -107 points |
| Q3 2025 | -90% | -28 points |
| Q2 2025 | -114% | -114 points |
| Q1 2025 | -222% | -148 points |
| Q4 2024 | -114% | -85 points |
AQST's operating margin was −191% last quarter, down 102 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AQST on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AQST on profitability, with a higher operating margin.
AQST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.6M | +$5.3M |
| Q2 2026 | -$9.7M | -$1.6M |
| Q1 2026 | -$14.9M | +$8.7M |
| Q4 2025 | -$8.6M | -$2.1M |
| Q3 2025 | -$12.9M | -$924K |
| Q2 2025 | -$8M | -$980K |
| Q1 2025 | -$23.5M | -$13.1M |
| Q4 2024 | -$6.5M | -$1.5M |
AQST has burned cash in almost every quarter: −$41M over the past year, against −$51M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AQST on cash generation, producing positive trailing cash flow while its opponent burns cash.
AQST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +555K shares |
| 1 year | +14% | +15M shares |
| 3 years | +94% | +60.9M shares |
| 5 years | +220% | +86.3M shares |
| Available history | +274% | +92M shares |
AQST has 126M diluted shares, up 14% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AQST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AQST Net Leverage
AQST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AQST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 9.9 | Oversold |
AQST's weekly RSI is 40 (neutral) and its Stochastic is 10 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AQST PE vs Healthcare Sector
AQST has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AQST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.11 | 13% below |
| 20 week MA | $4.26 | 16% below |
| 50 week MA | $4.32 | 17% below |
| 100 week MA | $4.14 | 14% below |
| 200 week MA | $3.42 | 4.4% above |
AQST has fallen below most of its moving averages, though it's still 4.4% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AQST on trend strength, trading above more of its moving averages.
AQST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.54 | $6.37 | +15% |
| 2021 | $6.37 | $4.03 | -37% |
| 2022 | $4.03 | $0.93 | -77% |
| 2023 | $0.93 | $2.02 | +117% |
| 2024 | $2.02 | $3.52 | +74% |
| 2025 | $3.52 | $5.99 | +70% |
| 2026 YTD | $5.99 | $3.57 | -40% |
AQST's yearly returns have swung widely, from +117% in 2023 to −77% in 2022. It's down 40% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AQST on returns for 2026, with the stronger performance.